Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

- Positive Pharmacokinetic Study Results on First INTELLITAB(TM) Product Demonstrates Proof-of-Concept -

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today introduced INTELLITAB(TM), the brand name for its proprietary abuse and misuse-deterrent technology platform. The INTELLITAB(TM) platform, which can deliver one or more therapeutic drugs in combination over periods of up to 24 hours, has the potential to provide a patient with a controlled release medication while minimizing the risk of intentional abuse or accidental misuse.

"Intentional abuse and accidental misuse of prescription medications is a serious and growing socio-health problem and increasingly becoming the focus of patients, public advocacy groups, government agencies and the global pharmaceutical industry," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "The development of safer pharmaceutical formulations is a major new direction for the industry, not unlike the advent of child-proof caps was to packaging several decades ago. It just makes sense that if we, as an industry, can offer patients less abusable formulations of existing medications, we should."